P&G Health Q2 Sales Rise 18%, PAT Jumps 26%

PGHL (PGHL) reported double-digit growth in its second-quarter FY27 results, with sales increasing 18% year-on-year to ₹376 crore for the quarter ended September 30, 2026. Profit after tax (PAT) rose 26% to ₹112 crore, supported by sales growth and productivity improvements across the value chain. According to the company, the performance was driven by strong brand fundamentals, effective retail execution, positive consumer response to new product innovations and strengthened go-to-market capabilities. Managing Director Milind Thatte highlighted the growing consumer focus on preventive healthcare and the positive response from consumers, patients and healthcare professionals to the company's science-backed healthcare products. The company also credited its consumer communication initiatives, healthcare professional awareness programmes and improved supply chain capabilities for supporting business growth. PGHL operates in India's vitamins, minerals and supplements (VMS) segment, with established brands including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Its strategy focuses on a portfolio of trusted healthcare brands, product superiority, innovation, retail execution and productivity. The latest results indicate continued growth in both revenue and profitability. Investors will monitor whether the company can sustain this momentum through new product launches, stronger distribution and continued demand for preventive healthcare products. Disclosure: I do not hold any position or financial interest in the mentioned stock.